胃癌术后的冠心病患者使用心脏毒性化疗药物的药学监护  

Pharmaceutical Care for One Case of Coronary Heart Disease Accompanied by Postoperative Gastric Cancer

作　　者：王明月[1,2] 吴薇 岳峰 裔照国[1] 徐静 WANG Mingyue;WU Wei;YUE Feng;YI Zhaoguo;XU Jing(department of Pharmacy,the Third PeopleJ s Hospital,Yancheng Jiangsu 224001,China;Department of Pharmacy,Zhongshan Hospital,Fudan University,Shanghai 200032,China)

机构地区：[1]盐城市第三人民医院药学科,江苏盐城224001 [2]复旦大学附属中山医院药剂科,上海200032

出　　处：《中国药物警戒》2019年第12期747-749,共3页Chinese Journal of Pharmacovigilance

摘　　要：目的探讨临床药师对1例术后合并冠心病的胃癌患者应用具有心脏毒性化疗药物的药学监护。方法通过分析对比胃癌术后常规化疗方案中药物的心脏毒性大小,选用适合该患者的化疗方案。结果氟尿嘧啶为胃癌术后辅助化疗的基础药物,由心脏毒性相对较小的雷替曲塞代替,同时联合奥沙利铂作为化疗方案。结论对于有心脏基础疾病的患者在应用化疗药物时需基于心脏毒性风险的评估,避开使用可诱发该种类心脏病的药物,降低药物诱发心脏病的风险。Objective To explore how clinical pharmacists can give pharmaceutical care by recommending cardiotoxic chemotherapy drugs for patients with coronary heart disease after gastric cancer surgery.Methods By analyzing and comparing the cardiotoxicity of conventional chemotherapy drugs after gastric cancer surgery,a proper treatment for the patient was selected.Results Fluorouracil is the basic drug used for postoperative adjuvant chemotherapy for gastric cancer.It was replaced by raltitrexed with less cardiotoxicity,which was combined with oxaliplatin as a chemotherapy regimen.Conclusion The selection of chemotherapy drugs should be based on assessment of the risk of cardiotoxicity among patients with heart-based diseases.

关 键 词：胃癌 化疗 冠状动脉性心脏病 直肠癌 药学监护 

分 类 号：R972[医药卫生—药品]